The government considers reassessing the full reimbursement for long-term illnesses: what does this really mean?

The long-term illnesses (ALD) scheme has long been a pillar of the French public health system, ensuring 100% reimbursement of care and treatments for nearly 14 million French people suffering from chronic or severe illnesses. This mechanism, which relies on Social Security and Health Insurance, guarantees extensive coverage and easier access to care, particularly for conditions such as diabetes, cancers, or Crohn’s disease. Yet, faced with a tightening budgetary context, the government, driven by a desire for significant savings estimated in the billions of euros, is now reconsidering this system. This reflection centers around the crucial issue of fully covered reimbursements, a historic foundation of French social protection.

Prime Minister François Bayrou has initiated the debate by announcing a desire to limit 100% reimbursement for certain treatments associated with ALD, especially targeting medications not directly linked to the diagnosed illness. This announcement highlights not only the need for financial adjustment but also critiques of sometimes questioned medical and administrative practices, where abuses or errors in categorizing care could inflate costs. The Ministry of Health and managing bodies such as the Primary Health Insurance Fund (CPAM) are hesitating between maintaining a system regarded as protective and implementing necessary corrective measures.

From this perspective, it is noteworthy that this approach does not solely aim to reduce costs but also to optimize expenses within a more responsible framework, in line with recommendations from mutual insurance and supplementary health plans. The review could include stricter criteria on the Reimbursement Plan and foster closer cooperation among healthcare professionals, pharmacists, and complementary insurers. The impact of this potential reform worries vulnerable patients but also raises the debate on finding the right balance between solidarity and economic sustainability in a context where costs related to chronic diseases continue to rise.

The long-term illnesses (ALD) scheme: comprehensive and essential coverage

The long-term illnesses (ALD) scheme is an essential component of the French public health system, designed to guarantee chronic patients 100% coverage for care related to their condition. Managed by Social Security and facilitated through the AMELI platform, it aims to remove financial barriers for often heavy and prolonged treatments.

More than 40 conditions are now covered, ranging from metabolic diseases such as diabetes to severe neurological disorders, including cancers. In 2022, nearly 14 million people benefited from this measure, representing about one-fifth of the French population. The scheme does not limit itself to hospitalizations or consultations; it also includes medications, nursing care, and sometimes medical devices essential for daily patient management.

This scheme operates based on strict medical criteria according to a list established by the Ministry of Health. Recognition of an ALD requires a detailed medical certificate, a mandatory process before the CPAM, which assigns the status and manages coverage. This organization ensures that only serious or chronic conditions justify this full coverage.

It is important to highlight the tangible benefits of this scheme:

• 📌 Facilitated access to expensive medications and treatments, especially for chemotherapies or antidiabetic treatments, with no out-of-pocket costs.
• 📌 Reduction of social inequalities by limiting economic obstacles to long-term care.
• 📌 Enhanced medical coordination among specialists, general practitioners, and paramedical teams.
• 📌 Psychological support and assistance for patients and their families, facilitated through care networks and sometimes related to disability recognition.

Chronic Disease	Approximate number of beneficiaries	Type of coverage	Examples of reimbursed treatments
Diabetes	4 million	100% reimbursement	Insulin, glucometers, specialized consultations
Cancer	2 million	100% reimbursement	Chemotherapies, radiotherapies, targeted medications
Crohn’s Disease	250,000	100% reimbursement	Anti-inflammatories, immunosuppressants, gastro consultations
Disabling Stroke	150,000	100% reimbursement	Rehabilitation, nursing care, anticoagulant treatments

This full coverage is a major achievement of the system and is already integrated into supplementary health insurance contracts, which often adapt to this already comprehensive coverage. Mutuals and additional insurers can thus extend their support to other expenses not covered by Health Insurance.

A necessary reevaluation: the financial and social stakes of 100% reimbursement for ALD

Facing a trajectory of rapidly rising expenditures, the government sees in the ALD scheme a significant potential for savings. The Prime Minister’s plan, which foresees a total reduction of 5 billion euros in social expenses, directly targets the full reimbursement of care related to long-term illnesses.

According to communicated data, these coverages concern more than 20% of the adult population, representing a major challenge for Social Security and the Health Insurance budget. The risk of exceeding expenditure caps is real in a context of demographic aging and increasing chronic disease prevalence.

Moreover, voices within health organizations and professional unions denounce certain abuses observed in the classification and reimbursement of medications. Pierre-Olivier Variot, president of the Union of Community Pharmacists’ Unions (USPO), emphasizes that:

• 💊 some medications, not directly linked to the declared ALD disease, are nonetheless reimbursed at 100%,
• 💊 hospital doctors sometimes classify treatments too broadly,
• 💊 conversely, errors omit essential costly medications, impacting patients.

This situation leads to questions about the Reimbursement Plan and proposes to remove certain cases from ALD status, especially for individuals in complete remission, raising the following questions:

1. 🔍 How to ensure a rational and targeted use of reimbursements?
2. 🔍 What guarantees for vulnerable patients to prevent care abandonment?
3. 🔍 What role for doctors and pharmacists in regulating coverage?

In response, the Primary Health Insurance Fund and the Ministry of Health are currently exploring measures to combat fraud and improve control over reimbursements, while respecting the fundamental right to health. Informational campaigns for professionals are being planned to remind them of the strict criteria of the scheme.

Reevaluation Stakes	Expected impacts	Proposed measures
Reduction in social spending	Savings up to 5 billion euros	Cumulative restriction of reimbursements outside direct link
Fight against abuse and fraud	Better resource management	Enhanced controls and prescriber training
Maintaining solidarity	Protection of patients in genuine need	Exiting ALD status for stabilized cases

This revision has now become part of the public debate and budget negotiations, raising concerns among various patient associations and health organizations. To better understand the tangible implications, it is essential to examine the mechanisms, stakeholders, and consequences of such a reform.

Conditions for ALD-related diseases and eligibility criteria

The ALD scheme covers an official list of recognized conditions by the Ministry of Health. This list includes more than forty diseases across various medical fields:

• 🧬 Endocrine and metabolic diseases (diabetes, hypothyroidism)
• 🧠 Neurological and neurodegenerative diseases (multiple sclerosis, Parkinson’s)
• 🫀 Severe cardiovascular diseases (disabling stroke, heart failure)
• 🩺 Cancers and leukemias
• 🦠 Infectious diseases of long duration (chronic hepatitis, HIV)
• 🦷 Chronic inflammatory diseases (rheumatoid arthritis, Crohn’s disease)

To be eligible for 100% coverage, several conditions must be met:

1. 📄 Submission of a precise medical certificate justifying the severity of the disease and the prolonged or disabling nature of the care.
2. 📋 Dossier processing by the local Primary Health Insurance Fund, which decides on granting ALD status.
3. 🔄 Regular updates to the medical file, including annual visits to ensure follow-up and adapt coverage.

The AMELI system centralizes these administrative procedures, offering patients easier access to their rights and reimbursement. Collaboration with healthcare professionals is key to ensuring coherent coverage.

Medical field	Examples of conditions	Estimated number of patients	Required follow-up type
Endocrinology	Type 1 and 2 diabetes	4 million	Regular blood tests and therapeutic adjustments
Oncology	Solid and hematological cancers	2 million	Chemotherapy, radiotherapy, specialized consultations
Neurology	Multiple sclerosis, disabling stroke	650,000	Rehabilitation, symptomatic treatment, neurological follow-up
Gastroenterology	Crohn’s disease, chronic hepatitis	400,000	Anti-inflammatory treatments, regular assessments

These strict criteria aim to protect the viability of the system while ensuring quality medical follow-up tailored to patients’ evolving needs. A delicate balance is sought between maximum support and economic efficiency.

Impact of the review on eligibility criteria

The contemplated change in managing full reimbursement could lead to a revision of access criteria. Notably, partial or complete removal from ALD status could be considered for stable or fully remission patients. This tightening raises questions about balancing rigorous medical assessment with social protection.

Impacts on patients: concerns and possible adjustments

The potential revision of full reimbursement raises significant concerns among affected populations. These long-term illnesses often affect vulnerable or weakened individuals for whom easy access to care without out-of-pocket costs is crucial for maintaining health and quality of life.

Several associations and bodies such as the Ligue contre le Cancer have expressed fears of care abandonment if coverage is reduced. This concern is based on:

• ⚠️ Possible increase in out-of-pocket costs for essential treatments.
• ⚠️ Increased risks of inequalities in access to care, especially in rural or underserved areas.
• ⚠️ Stress and anxiety linked to the loss of financial security regarding healthcare.

Despite these fears, some patients and professionals stress the need for constructive dialogue to adapt the system and prevent administrative errors or abuses. Several avenues are being considered:

• ✅ Strengthening communication between the CPAM, doctors, and patients.
• ✅ Implementing systematic evaluation of reimbursed treatments based on their direct link to the condition.
• ✅ Promoting personalized care plans, including supplementary health coverage and local mutual insurance.

This dialogue is essential to prevent the reform from further weakening already ill individuals. Healthcare professionals are called to play an increased role in adjusting prescriptions and tracking treatments.

Potential consequences	Patients affected	Proposed adaptation measures
Increase in out-of-pocket costs	Elderly and chronic patients	Optimizing supplementary health and social aid
Care abandonment	Vulnerable populations	Strengthening support from health organizations
Territorial inequalities	Rural and underserved areas	Creating specific schemes and localized follow-up

The role of healthcare professionals in managing ALD reimbursements

General practitioners, specialists, and pharmacists are essential players in the proper functioning of the ALD scheme. Their responsibility in selecting treatments and ensuring quality prescriptions largely determines the reliability of reimbursements and the fight against abuse.

According to Pierre-Olivier Variot, vigilance at the hospital level must be strengthened, as a tendency to categorize medications under the 100% ALD category has been observed, exacerbating Social Security deficits. Conversely, errors such as omitting coverage for essential treatments are also criticized.

To improve this management, the following measures are considered:

• 🏥 Enhanced training and regular updates for prescribers on ALD criteria and reimbursement rules.
• 📊 Use of digital tools, including AMELI, to support real-time prescriptions and detect anomalies.
• 🤝 Increased collaboration between pharmacists, doctors, and health insurance organizations to better control prescriptions.

Actor	Key role	Planned actions
General practitioners	Assessment of disease and prescription	Ongoing training and verification of links with ALD
Hospital specialists	Monitoring of complex treatments	Strengthening controls and internal audits
Community pharmacists	Dispensing and verification of prescriptions	Reporting inconsistencies and collaborating with CPAM

This multifaceted cooperation fits into a broader approach of optimization, aimed at preserving access to care while consolidating the economic viability of the system, within the larger framework of public policies led by the Ministry of Health.

The challenges faced by supplementary health insurers in the face of ALD reform

Mutual insurance companies and supplementary insurers play an essential intermediary role with patients to cover expenses not covered by Social Security, especially in the event of changes to the ALD scheme. Their position is strategic amid this uncertain environment.

In the event of a possible reduction in full reimbursement, mutual contracts will need to adapt by offering enhanced or specialized plans for chronic patients. In some cases, these supplementary insurers might be encouraged to revise their reimbursement scales and modify their contributions, directly impacting insured individuals.

The main challenges facing these organizations include:

• 💼 Adapting offers to remain attractive and competitive in a sensitive market.
• 💼 Managing financial risks associated with potential increases in out-of-pocket costs.
• 💼 Strengthening cooperation with Social Security and healthcare institutions to optimize care pathways.
• 💼 Implementing prevention and support actions to limit complications and costly hospitalizations.

Mutual challenges	Expected actions	Consequences for members
Reassessment of guarantees	Creation of specific ALD options	Potential increase in contributions
Risk management	Detailed analysis of patient files	Personalized reimbursements
Supporting patients	Prevention and follow-up programs	Better quality of life

These changes, although challenging, could help establish a more sustainable model aligned with economic and health realities. This evolution is closely monitored by organizations such as the Primary Health Insurance Fund and the Ministry of Health, as well as sector professionals.

Perspectives and risks associated with ALD reimbursement reform

This reform proposed by the government is generating debates and controversies across various spheres. Beyond budgetary concerns, it also involves ethical and social issues at the forefront, balancing financial flexibility with patient protection.

Proponents of the current system emphasize that partial or total removal of the 100% reimbursement could:

• ⚖️ Widen inequalities in access to care, especially for vulnerable populations,
• ⚖️ Lead to treatment non-adherence due to financial concerns,
• ⚖️ Increase the burden on associations and health organizations to compensate for gaps.

Conversely, reform advocates highlight:

• 📉 the necessity of controlling public expenses to ensure the system’s sustainability,
• 📉 targeted reduction of abuses to improve efficiency,
• 📉 redirecting aid toward more severe or active cases.

Given these issues, public debate is intensifying, and the government must balance conflicting interests while maintaining citizens’ trust in the healthcare system. The decisions made will have long-term repercussions on the country’s social and health policies.

Argument	For reform	Against reform
Budgetary savings	Estimated reduction of 5 billion euros	Potential higher indirect costs on public health
Access to care	Better resource allocation	Fragilization of chronic patients
Social solidarity	Targeted optimization	Violation of the principle of equality

Health organizations, including the Primary Health Insurance Fund, continue to weigh options with pragmatic proposals, where solidarity remains fundamental while adapting financial mechanisms to economic realities.

Monitoring and digital tools to ensure optimized reimbursement

The integration of new digital technologies into the ALD system is seen as a major opportunity to make the reimbursement plan more transparent, efficient, and reliable. The AMELI portal plays a crucial role in this context, enabling notably:

• 📱 The dematerialized management of files and rapid updating of information on conditions and treatments.
• 📱 Automatic monitoring of prescriptions with alerts for anomalies or abuses.
• 📱 Easier communication among doctors, pharmacists, patients, and Social Security organizations.

Additionally, supplementary applications are being developed to support professionals and ensure daily monitoring of patients with chronic diseases, thus limiting errors and encouraging better adherence to therapies.

Digital tool	Functionality	Expected impact
AMELI	The official Social Security platform	Centralization of data and real-time monitoring
Automatic alerts	Rapid detection of abnormal reimbursements	Reduction of abuses
Patient mobile applications	Personalized follow-up and reminders	Improved adherence

These innovations are key levers to support the reform in modernizing the public health system and improving patients’ quality of life.

FAQ: what you need to know about the reevaluation of ALD reimbursements

• ❓ What is the ALD status?

  The ALD status recognizes a chronic or serious disease justifying 100% reimbursement of care related to that condition.

• ❓ Why does the government want to reevaluate ALD reimbursement?

  To control rapidly increasing social expenses and limit potential abuses in reimbursements.

• ❓ What impacts for patients?

  A possible increase in out-of-pocket costs, especially for treatments not directly related to the disease, with a risk of care abandonment if no additional support is provided.

• ❓ How will doctors and pharmacists be involved?

  They will need to strengthen rigor in prescribing and dispensing treatments, in cooperation with CPAM and health insurance organizations.

• ❓ What role for supplementary health insurers?

  Mutual insurance companies will need to adapt by offering personalized plans and supporting patients in financing treatments not covered.

For more detailed information, see especially the following articles:

• Budget 2026: long-term illnesses (ALD) under François Bayrou’s scrutiny
• Budget 2026: savings, what is the long-term illness scheme targeted by François Bayrou?
• Budget: what does the 100% reimbursement for chronically ill patients that Bayrou wants to revisit?
• Health insurance reimbursement: how it works and prospects
• Cooperation between insurance and mutuals to fight fraud

Source: www.capital.fr